Park Seong-Hoo, Park Jeongjin, Yoo Eunhee, Jung Jaeeun, Park Mi-Ryeong, Kim Soyoung, Kim Jong-Lae, Lee Jong Wook, Kim Ok-Kyung, Lee Minhee
Clinical Nutrition Institute, Kyung Hee University, Seoul 02447, Republic of Korea.
Division of Food and Nutrition and Human Ecology Research Institute, Chonnam National University, Gwangju 61186, Republic of Korea.
Int J Mol Sci. 2025 May 29;26(11):5230. doi: 10.3390/ijms26115230.
This study aims to evaluate the anti-obesity effects of Ashwagandha (, AS), Herbich var. (Maxim.) Kitamura (C), and their combination (AS:C = 3:1, ASC) in high-fat-diet (HFD)-induced obese animal models. Key metabolic parameters, including body weight, lipid metabolism, adipogenesis, energy expenditure, and glucose homeostasis, were assessed. HFD-fed mice were supplemented with AS25, C25, or ASC at different concentrations (ASC25, ASC50, and ASC100). Body weight, food efficiency ratio (FER), organ and adipose tissue weights were measured. Serum biochemical markers, including lipid profiles, glucose, insulin, and liver enzymes, were analyzed. Western blot analysis was conducted to assess the expression of key proteins involved in adipogenesis, lipogenesis, lipolysis, and energy metabolism. ASC complex supplementation, particularly at higher doses (ASC100), significantly reduced body weight gain, liver weight, and total white adipose tissue (WAT) accumulation. ASC complex groups exhibited improved lipid profiles, with reductions in triglycerides, total cholesterol, and low-density lipoprotein (LDL). Serum glucose, insulin, and HbA1c levels were significantly reduced, suggesting improved insulin sensitivity. Western blot analysis revealed that ASC complex supplementation downregulated key adipogenic markers, including PPARγ, C/EBPα, and SREBP1c, while enhancing adiponectin levels. ASC complex also promoted energy metabolism by increasing the phosphorylation of AMPK and UCP1 expression, indicative of enhanced thermogenesis and lipid oxidation. ASC complex supplementation demonstrates a potent anti-obesity effect by modulating adipogenesis, lipid metabolism, and energy expenditure. The findings suggest that ASC complex could serve as a promising natural therapeutic strategy for obesity and metabolic disorders. Further research, including clinical trials, is warranted to validate its efficacy and safety in human populations.
本研究旨在评估南非醉茄(AS)、毛喉鞘蕊花(C)及其组合(AS:C = 3:1,ASC)在高脂饮食(HFD)诱导的肥胖动物模型中的抗肥胖作用。评估了包括体重、脂质代谢、脂肪生成、能量消耗和葡萄糖稳态在内的关键代谢参数。给高脂饮食喂养的小鼠补充不同浓度的AS25、C25或ASC(ASC25、ASC50和ASC100)。测量了体重、食物效率比(FER)、器官和脂肪组织重量。分析了血清生化标志物,包括血脂谱、葡萄糖、胰岛素和肝酶。进行蛋白质免疫印迹分析以评估参与脂肪生成、脂质生成、脂肪分解和能量代谢的关键蛋白的表达。补充ASC复合物,特别是高剂量(ASC100)时,可显著降低体重增加、肝脏重量和总白色脂肪组织(WAT)积累。ASC复合物组的血脂谱得到改善,甘油三酯、总胆固醇和低密度脂蛋白(LDL)降低。血清葡萄糖、胰岛素和糖化血红蛋白(HbA1c)水平显著降低,表明胰岛素敏感性提高。蛋白质免疫印迹分析显示,补充ASC复合物可下调关键的脂肪生成标志物,包括过氧化物酶体增殖物激活受体γ(PPARγ)、CCAAT/增强子结合蛋白α(C/EBPα)和固醇调节元件结合蛋白1c(SREBP1c),同时提高脂联素水平。ASC复合物还通过增加腺苷酸活化蛋白激酶(AMPK)的磷酸化和上调解偶联蛋白1(UCP1)表达促进能量代谢,表明产热和脂质氧化增强。补充ASC复合物通过调节脂肪生成、脂质代谢和能量消耗显示出强大的抗肥胖作用。研究结果表明,ASC复合物可能是一种有前景的治疗肥胖和代谢紊乱的天然策略。有必要进行进一步研究,包括临床试验,以验证其在人群中的疗效和安全性。